lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12...3233343536373839404142...4546»
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Biomarker, Clinical, PK/PD data, Journal, Monotherapy:  Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient. (Pubmed Central) -  Jan 8, 2020   
    The lopinavir/ritonavir plasma concentrations at standard doses were significantly above the recommended levels...After the withdrawal of tenofovir disoproxil and the establishment of individualized protease inhibitor monotherapy at reduced doses, a decrease in the intensity of adverse events was observed, while the clinical outcomes were maintained. The pharmacokinetic-pharmacogenetic analysis was shown to be a tool of huge interest for the management and durability of antiretroviral therapy.
  • ||||||||||  abacavir / Generic Mfg., lopinavir/ritonavir / Generic Mfg.
    Journal:  Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. (Pubmed Central) -  Nov 22, 2019   
    Once body weight > 3 kg and gestational age > 44 weeks, Abacavir replaced Zidovudine...Mean quotients were within the average range: Global Griffiths score was 103.6 ± 10.9 and mean quotients on the subscales ranged from lowest 95.9 ± 13.4 for locomotor to highest 112.8 ± 11.3 for hearing-and-language. Preliminary findings in this small group suggest that early neurodevelopmental scores are within the normal range in infants with perinatal HIV infection who started ART at a median of 6 days.
  • ||||||||||  lopinavir/ritonavir / Generic Mfg.
    New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1933;    
    Mothers received treatment with lopinavir/ritonavir +zidovudine/lamivudine through the whole pregnancy in 111 cases, other antiretroviral regimens in 43 cases, and in 9 cases the mothers did not receive any treatment, being tested for HIV at birth. Evaluation of pregnant HIV-positive women and prophylaxis for new-born infants in the evaluated period was conducted according to protocols, which resulted in a small percentage of HIV-positive children(1,8%).
  • ||||||||||  lopinavir/ritonavir / Generic Mfg.
    New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_1123;    
    Mothers received treatment with lopinavir/ritonavir +zidovudine/lamivudine through the whole pregnancy in 111 cases, other antiretroviral regimens in 43 cases, and in 9 cases the mothers did not receive any treatment, being tested for HIV at birth. Evaluation of pregnant HIV-positive women and prophylaxis for new-born infants in the evaluated period was conducted according to protocols, which resulted in a small percentage of HIV-positive children(1,8%).
  • ||||||||||  lopinavir/ritonavir / Generic Mfg.
    New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi (Exhibition hall) -  Nov 15, 2019 - Abstract #EACS2019EACS_685;    
    Mothers received treatment with lopinavir/ritonavir +zidovudine/lamivudine through the whole pregnancy in 111 cases, other antiretroviral regimens in 43 cases, and in 9 cases the mothers did not receive any treatment, being tested for HIV at birth. Evaluation of pregnant HIV-positive women and prophylaxis for new-born infants in the evaluated period was conducted according to protocols, which resulted in a small percentage of HIV-positive children(1,8%).
  • ||||||||||  lopinavir/ritonavir / Generic Mfg.
    Clinical, Journal:  A clinical prediction rule for protease inhibitor resistance in patients failing second-line antiretroviral therapy. (Pubmed Central) -  Nov 4, 2019   
    Our CPR to select patients for GART requires external validation before implementation.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
  • ||||||||||  lopinavir/ritonavir / Generic Mfg.
    Clinical, PK/PD data, Journal:  Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. (Pubmed Central) -  Nov 2, 2019   
    Monte Carlo simulations of the final model using current World Health Organization weight-band dosing recommendations demonstrated that participants younger than 6 months of age had a lower area under the drug concentration-time curve (94.8 vs >107.4 μg hr/mL) and minimum observed concentration of drug in blood plasma (5.0 vs > 7.1 μg/mL) values compared to older children and adults. Although World Health Organization dosing recommendations include a larger dosage (mg/m ) in infants to account for higher apparent clearance, they still result in low LPV concentrations in many infants younger than 6 months of age receiving the liquid formulation.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, lopinavir/ritonavir / Generic Mfg.
    Biomarker, Clinical, Journal:  Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children: 7-year follow-up of the IMPAACT P1060 trial. (Pubmed Central) -  Oct 31, 2019   
    P2
    Given the virologic superiority of LPV/r-based regimens in young children and open questions regarding the roll-out of dolutegravir in resource-limited settings, children are currently being maintained on LPV/r-based regimens. Our results suggest continual assessment of total cholesterol among young children initiating a LPV/r-based regimen to monitor cardiometabolic health.
  • ||||||||||  lopinavir/ritonavir / Generic Mfg.
    Clinical, Journal:  HIV Second-Line Failure and Drug Resistance at High- and Low-Level Viremia in Western Kenya. (Pubmed Central) -  Oct 31, 2019   
    High resistance upon 2-line failure exists at levels above and below guidelines-recommended virologic-failure threshold, impacting future treatment options. Optimization of care should include increased VL monitoring, resistance testing and 3-line ART access, and consideration of lowering the virologic failure threshold, though this demands further investigation.
  • ||||||||||  tenofovir disoproxil fumarate / Generic Mfg.
    Journal:  Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring. (Pubmed Central) -  Oct 4, 2019   
    We studied subjects who, after a median of 4.2 years of ART, replaced zidovudine or stavudine with tenofovir disoproxil fumarate while continuing lamivudine and an NNRTI...At T1, 79/87 (90.8%) subjects remained on NNRTI-based ART, 5/87 (5.7%) had introduced lopinavir/ritonavir due to immunological failure, and 3/87 (3.4%) had interrupted ART...Tenofovir, lamivudine and efavirenz selected for K65R, K70E/T, L74I/V and Y115F, alongside M184V and multiple NNRTI RAMs; this resistance profile was accompanied by high viral loads and low CD4 cell counts. Viraemia on tenofovir, lamivudine and efavirenz led to complex resistance patterns with implications for continued drug activity and risk of onward transmission.
  • ||||||||||  Truvada (emtricitabine/tenofovir disoproxil fumarate) / Gilead
    A ROLE FOR HAART AND TEVAR IN HIV-INDUCED LARGE VESSEL VASCULITIS (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_1560;    
    Given the paucity of reports of HIV-induced large-vessel vasculitis, data regarding optimal timing of vascular repair, approach of open vs. endovascular repair and the temporal relationship between the contraction of HIV and the development of vasculitis remains unclear. Ongoing report of new cases and investigation through systematic review of existing cases is warranted.
  • ||||||||||  lopinavir+ ritonavir / generics
    Clinical, Journal:  Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. (Pubmed Central) -  Sep 6, 2019   
    Counselling should focus on ensuring that caregivers can confidently administer pellets and are able to instruct others, to ensure high uptake and good adherence to treatment. LPV/r pellets may be an acceptable substitute for other available forms of LPV/r for eligible children under three years if they are currently on or in need of LPV/r-containing regimens; however, challenges with administration still highlight the need for improved drug formulations for paediatric ART patients.
  • ||||||||||  Epzicom (abacavir/lamivudine) / ViiV Healthcare
    Side Rffects of Antiretroviral Therapy in Children with HIV in a Referral Center in Mexico () -  Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2938;    
    We observe that adverse effects are frequent, almost the half, in pediatric population, it depends on the antiretroviral selection, for children we had only a few options because of the little doses they need or the inability to swallow tablets. It´s important to monitor and control all the adverse effects because they increase morbidity and mortality, especially dyslipidemia, that has been associated with cardiovascular risk and it was the most common effect found in our study.
  • ||||||||||  lopinavir+ ritonavir / generics
    Factors Associated with Hypertension in Young Adults with Perinatally-Acquired HIV Infection: a Case-Control Study () -  Aug 26, 2019 - Abstract #IDWeek2019IDWeek_1120;    
    Cases had lower odds of a history of treatment with lopinavir/ritonavir (LPV/r)...Additionally, there may be as yet unidentified risk factors for HTN among PHIV which require further exploration. Given the large and growing population of PHIV entering adulthood worldwide, it is imperative to explore risk factors for and effects of HTN in large, diverse PHIV populations. 
  • ||||||||||  lopinavir+ ritonavir / generics
    Journal:  Profile of antiretroviral agents use in Colombia (Pubmed Central) -  Aug 23, 2019   
    Patients undergoing antiretroviral treatment are receiving medications with elevated intrinsic values at the recommended doses and present comorbidities associated with chronic agerelated conditions. However, these patients receive a great variety of regimens that are not included in the clinical practice guidelines.
  • ||||||||||  Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Journal:  Reciprocal effects of antiretroviral drugs used to treat HIV infection on the fibroblast growth factor-21/β-Klotho system. (Pubmed Central) -  Aug 21, 2019   
    In human hepatocytes and adipocytes, known target cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination exerted inhibitory effects on KLB gene expression...In conclusion, current in vitro screen study identifies the antiretroviral drugs that affect FGF21/KLB expression in human cells. Present results could have important implications for the management of co-morbidities resulting from side effects of specific antiretroviral drugs for the treatment of HIV-infected patients.
  • ||||||||||  Trial completion date, Trial primary completion date:  RESIST-2: 2nd-line ART for HIV-2 Infection (clinicaltrials.gov) -  Aug 19, 2019   
    P=N/A,  N=150, Recruiting, 
    Present results could have important implications for the management of co-morbidities resulting from side effects of specific antiretroviral drugs for the treatment of HIV-infected patients. Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  Simplified Treatment of Anti-retrovirus in China (C-STAR) (clinicaltrials.gov) -  Jul 30, 2019   
    P=N/A,  N=600, Recruiting, 
    The results suggest that dual therapy of LPV/r plus 3TC is non-inferior to the first-line triple-therapy regimen in China. Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Trial completion:  FIT-2: First-Line Treatment for HIV-2 (clinicaltrials.gov) -  Jul 22, 2019   
    P2b,  N=210, Completed, 
    Therefore, HIV care in resource-limited settings should prioritize strategies to improve adherence and targeted viral load testing over drug resistance testing for selecting NRTs during protease-based second-line switch. Active, not recruiting --> Completed